ATE462787T1 - Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington - Google Patents
Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntingtonInfo
- Publication number
- ATE462787T1 ATE462787T1 AT07290751T AT07290751T ATE462787T1 AT E462787 T1 ATE462787 T1 AT E462787T1 AT 07290751 T AT07290751 T AT 07290751T AT 07290751 T AT07290751 T AT 07290751T AT E462787 T1 ATE462787 T1 AT E462787T1
- Authority
- AT
- Austria
- Prior art keywords
- huntington
- disease
- treatment
- application
- type
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 3
- 230000002441 reversible effect Effects 0.000 title 1
- 230000006807 siRNA silencing Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 238000011808 rodent model Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290751A EP2014769B1 (en) | 2007-06-18 | 2007-06-18 | Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE462787T1 true ATE462787T1 (de) | 2010-04-15 |
Family
ID=38476952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07290751T ATE462787T1 (de) | 2007-06-18 | 2007-06-18 | Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8217018B2 (enExample) |
| EP (1) | EP2014769B1 (enExample) |
| JP (1) | JP5401451B2 (enExample) |
| AT (1) | ATE462787T1 (enExample) |
| CA (1) | CA2690730C (enExample) |
| DE (1) | DE602007005629D1 (enExample) |
| WO (1) | WO2009007855A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2297341A4 (en) * | 2008-05-09 | 2013-01-09 | Univ British Columbia | METHOD AND COMPOSITIONS FOR TREATING MORBUS HUNTINGTON |
| US8679750B2 (en) | 2008-05-09 | 2014-03-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington'S disease |
| ES2616051T3 (es) | 2008-12-02 | 2017-06-09 | Wave Life Sciences Japan, Inc. | Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| WO2011097644A2 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| WO2011097643A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| EP2591356A1 (en) * | 2010-07-09 | 2013-05-15 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Method for in-vitro monitoring of neuronal disorders and use thereof |
| EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| JP6128529B2 (ja) | 2011-07-19 | 2017-05-17 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | 官能化核酸の合成のための方法 |
| ES2651514T3 (es) | 2011-08-11 | 2018-01-26 | Ionis Pharmaceuticals, Inc. | Compuestos oligoméricos gapados que comprenden deoxirribonucleósidos modificados en 5 ' -en la brecha y usos de ellos |
| MX374399B (es) | 2012-02-29 | 2025-03-06 | Sangamo Biosciences Inc | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. |
| US9598458B2 (en) | 2012-07-13 | 2017-03-21 | Wave Life Sciences Japan, Inc. | Asymmetric auxiliary group |
| MX356830B (es) | 2012-07-13 | 2018-06-15 | Shin Nippon Biomedical Laboratories Ltd | Adyuvante de acido nucleico quiral. |
| US9982257B2 (en) | 2012-07-13 | 2018-05-29 | Wave Life Sciences Ltd. | Chiral control |
| EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHOD FOR MONITORING THE C9ORF72 EXPRESSION |
| KR20150070278A (ko) * | 2012-10-15 | 2015-06-24 | 아이시스 파마수티컬즈 인코포레이티드 | C9orf72 발현 조절용 조성물 |
| JP2016516804A (ja) | 2013-04-17 | 2016-06-09 | ファイザー・インク | 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体 |
| EP3055414A4 (en) | 2013-10-11 | 2017-07-19 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| US10369201B2 (en) * | 2013-11-11 | 2019-08-06 | Sangamo Therapeutics, Inc. | Methods and compositions for treating Huntington's disease |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| DK3094728T3 (da) | 2014-01-16 | 2022-05-16 | Wave Life Sciences Ltd | Kiralt design |
| CA2947035A1 (en) * | 2014-05-08 | 2015-11-12 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
| SMT202000165T1 (it) | 2015-04-16 | 2020-05-08 | Ionis Pharmaceuticals Inc | Composizioni per modulare l'espressione di c9orf72 |
| MA43072A (fr) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
| MA45270A (fr) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
-
2007
- 2007-06-18 DE DE602007005629T patent/DE602007005629D1/de active Active
- 2007-06-18 EP EP07290751A patent/EP2014769B1/en not_active Not-in-force
- 2007-06-18 AT AT07290751T patent/ATE462787T1/de not_active IP Right Cessation
-
2008
- 2008-06-18 JP JP2010512808A patent/JP5401451B2/ja not_active Expired - Fee Related
- 2008-06-18 WO PCT/IB2008/002603 patent/WO2009007855A2/en not_active Ceased
- 2008-06-18 US US12/665,137 patent/US8217018B2/en not_active Expired - Fee Related
- 2008-06-18 CA CA2690730A patent/CA2690730C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2690730A1 (en) | 2009-01-15 |
| US8217018B2 (en) | 2012-07-10 |
| JP5401451B2 (ja) | 2014-01-29 |
| EP2014769B1 (en) | 2010-03-31 |
| EP2014769A1 (en) | 2009-01-14 |
| WO2009007855A3 (en) | 2009-04-02 |
| JP2010530239A (ja) | 2010-09-09 |
| US20100299768A1 (en) | 2010-11-25 |
| DE602007005629D1 (de) | 2010-05-12 |
| CA2690730C (en) | 2018-07-31 |
| WO2009007855A2 (en) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE462787T1 (de) | Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington | |
| WO2006084209A3 (en) | Rnai expression constructs | |
| ATE521711T1 (de) | In-vivo-screening-modelle zur behandlung der alzheimer-krankheit und anderer erkrankungen in zusammenhang mit dem qpct-gen | |
| WO2012067970A3 (en) | Transcriptional repression leading to parkinson's disease | |
| EP2303292A4 (en) | COMPOSITIONS WITH CARDIAL STEM CELLS WITH OVEREXPRESSION OF SPECIFIC MICRORNAS AND METHOD FOR THEIR USE IN THE REPAIR OF THE CARED MYOCARDIC | |
| WO2010017562A3 (en) | Induced pluripotent stem cells | |
| EP2414548A4 (en) | GENE EXPRESSION ANALYSIS IN SINGLE CELLS | |
| EP2250497A4 (en) | CELL PROCESSING AND / OR ENRICHMENT PROCESS | |
| WO2008144021A3 (en) | Ex vivo methods for validating substance testing with human organs and/or tissues | |
| WO2013158309A3 (en) | Non-disruptive gene targeting | |
| UY32361A (es) | Gen de delta-endotoxina axmi-150 y métodos de uso del mismo | |
| IN2009DN07390A (enExample) | ||
| BR112013000267A2 (pt) | produção de cassete de dna linear funcionalizado e distribuição mediada por ponto quântico/nanopartícula em plantas | |
| EP2641911A3 (en) | Compositions and methods for re-programming cells without genetic modification | |
| ATE519777T1 (de) | Magnetosomen-genexpression in eukaryotischen zellen | |
| WO2007064846A3 (en) | COMPOSITIONS AND METHODS OF USING siRNA TO KNOCKDOWN GENE EXPRESSION AND TO IMPROVE SOLID ORGAN AND CELL TRANSPLANTATION | |
| EP1874922A4 (en) | METHOD USING STROMA CELLS FROM UMBILICAL CORD BLOOD TO DEVELOP AND GRAFT NUCLEAR CELLS DERIVED FROM UMBILICAL CORD BLOOD | |
| EP2285968A4 (en) | CHIMERIC COMPOSITIONS AND METHOD FOR REGULATING GENE EXPRESSION IN PLANTS | |
| PL2271935T3 (pl) | Sposób i zestaw do ex vivo oceny reakcji nowotworu na warunki badania | |
| BR112013007041A2 (pt) | animal não humano, descendente, linhagem de células, tecido, explante de órgão, ou cultura dos mesmos, uso do modelo de doenças inflamatórias e métodos para o rastreio de compostos anti-inflamatórios e para a avaliação | |
| EP2325327A4 (en) | METHOD FOR ASSESSING SPECIFIC STORAGE OF D-GLUCOSE IN CELLS | |
| ATE555384T1 (de) | Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika | |
| Čunderlíková | Clinical significance of immunohistochemically detected extracellular matrix proteins and their spatial distribution in primary cancer | |
| EP1963514A4 (en) | PROCESS FOR THE PHOTOTRANSFICATION OF NUCLEIC ACID IN LIVING CELLS | |
| EP2659404A4 (en) | CELLS WITH DESTROYED EXPRESSION OF PROTEINS INVOLVED IN ADME AND TOXICOLOGY PROCEDURES THEREFOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |